Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?

Title: Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?

Volume: 7 Issue: 7

Author(s): S. Peter Stawicki, Melanie Lyons, Marianne Aloupis, Babak Sarani, S. Peter Stawicki, Melanie Lyons, Marianne Aloupis and Babak Sarani

Affiliation:

Keywords: Selenium supplementation, intensive care unit, critically ill patients, review of clinical trials

Abstract: The importance of the trace element selenium for human health is well established. Selenium plays a central role in the formation of selenocysteine, a modified amino acid located in the catalytic center of selenoenzymes. The crucial role of selenium in these enzymes revolves around the maintenance of many redox systems in cellular and extracellular compartments. In addition, selenium plays an important role in thyroid hormone metabolism. Several clinical trials of selenium supplementation in critically ill patients have been conducted to date, providing an interesting and provoking mix of findings. Despite some promising results, no definitive answers regarding the effects of selenium supplementation on critically ill patient mortality or morbidity exist. Further research in the setting of well-designed, prospective, randomized trials is necessary to better define the role of selenium supplementation in critically ill patients.

Cite this article as:

S. Peter Stawicki , Melanie Lyons , Marianne Aloupis , Babak Sarani , Stawicki Peter S., Lyons Melanie, Aloupis Marianne and Sarani Babak, Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?, Mini-Reviews in Medicinal Chemistry 2007; 7 (7) . https://dx.doi.org/10.2174/138955707781024526